Full-Time
Development Engineer 2
Sustaining
Posted on 7/3/2026
Zimmer Biomet Holdings
10,001+ employees
Develops joint replacement, robotics, smart implants
No salary listed
Bengaluru, Karnataka, India
Hybrid
Three days in-office per week required.
 Mechanical Engineering (1) |
|---|
Get referred to Zimmer Biomet Holdings
Find people who can refer or advise you
- Bachelor's Degree in Engineering or relevant degree and 1 year of relevant experience
- Microsoft Office Suite software proficiency required
- Travel up to 5%
- Executes sustaining projects with limited supervision
- Authors and releases Engineering Change Orders (ECOs); ensures compliance
- Participates in root cause and CAPA execution
- Supports cost reduction and supplier change initiatives
- Identifies incremental product/process improvements
- Contributes to standardization of sustaining documentation
- Minimum B.S. degree from an ABET accredited school (or global equivalent) in Mechanical Engineering, Mechanical Engineering Technology, Biomedical Engineering, Bioengineering, Biomedical Engineering Technology, Bioengineering Technology, Mechatronics Engineering, Aerospace Engineering or Aeronautical Engineering
- 1 to 3 years of full-time (including relevant Zimmer Biomet Coop/Intern) engineering experience
- Knowledge of ASME Geometric Dimensioning and Tolerancing standards with application to product design
- Knowledge of various manufacturing processes (including subtractive machining, anodization, additive manufacturing, forging, casting, plastic molding) and material science for application in new product development
- FDA QSR and EU MDR medical device regulatory requirements, and industry/regulatory body recognized technical product standards knowledge
- Statistics knowledge with application to sample size determination and null hypothesis testing
- Medical device orthopedic product design experience
- Demonstrated good written and verbal communication skills including presentation skills required
Zimmer Biomet manufactures and markets musculoskeletal medical devices and instruments for joint replacement, surgical trauma, and sports medicine. Its products include joint implants, surgical tools, and smart implants, often supported by robotic-assisted surgery systems. The company develops, produces, and sells these devices and provides services such as medical education and training to healthcare professionals to support procedures and outcomes. Compared with competitors, Zimmer Biomet benefits from a long history (over 90 years), a global footprint, and a focus on integrated solutions that combine advanced implants with robotics technology and education partnerships. Its goal is to advance patient care by delivering reliable devices, technologies, and professional training that improve surgical outcomes and collaboration with healthcare providers.
Company Size
10,001+
Company Stage
IPO
Headquarters
Warsaw, Indiana
Founded
1927
Get referred to Zimmer Biomet Holdings
Find people who can refer or advise you
Simplify's Take
What believers are saying
- The $140M iovera° acquisition adds $24.2M non-opioid revenue and aligns with opioid legislation.
- Hiring 500 Bengaluru staff for AI robotics strengthens India as a global innovation capability hub.
- Securing $2.75B credit facilities ensures liquidity for acquisitions and sustains a 5.0-to-1.0 debt ratio.
What critics are saying
- Stryker’s Mako robot displaces Zimmer’s ROSA in knee arthroplasty, causing high capital sales loss soon.
- U.S. sales force transformation causes surgeon outreach gaps and stalls organic growth at 1–3% in 2026.
- Johnson & Johnson’s next-gen hip implants with AI navigation directly erode Zimmer’s $2.09B hip franchise growth.
What makes Zimmer Biomet Holdings unique
- Zimmer leads with 90+ years of musculoskeletal expertise and a comprehensive joint replacement portfolio.
- The company integrates ROSA robotics and AI-driven smart implants across its surgical solutions.
- Zimmer offers non-opioid pain relief via the newly acquired iovera° cryoneurolysis device.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Wellness Program
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 1%2 year growth
↑ 2%Trust builds capability: Paula Ordoñez Angel on growing a GCC beyond the original blueprint. Heads of Global Capability Centers are often recognised for operational excellence, scale and efficiency. Yet behind every successful centre is a leadership philosophy that determines whether it remains a delivery organisation or evolves into a trusted strategic partner. Visual Art & Design In this edition of GCC Voices, I spoke with Paula Ordoñez Angel, former Americas GBS Site Director and Country General Manager at Zimmer Biomet, about scaling one of Latin America's most respected Global Business Services organisations. During her leadership, the Colombia GBS expanded from an initial plan of 200 to 300 professionals into an organisation of around 600 employees supporting finance, HR, supply chain, engineering, IT and commercial operations across the Americas. Discover more Communicating Business & Industrial Rather than attributing that growth to aggressive migration plans, Paula believes it resulted from something far more valuable: organisational trust. Watch the interview on YouTube: https://youtu.be/lPuYGjrgYqc Growth begins when capability creates demand. One of the most revealing insights from its discussion was that transformational growth rarely follows a predefined roadmap forever. Paula explained that the turning point wasn't marked by a single meeting or executive decision. Instead, she noticed that conversations with business leaders began changing. Initially, discussions centred on scheduled transitions and predefined migration plans. Over time, however, leaders began asking a different question: "Can Colombia take on this capability?" That subtle shift represented something much larger. Management Instead of following an established migration programme, the business was actively seeking opportunities because it trusted the centre's capability. As Paula reflected: "We were really growing because there was additional investment in our GBS sites because of the capabilities that we were able to grow." That confidence opened the door to functions far beyond the original scope, including engineering, medical affairs, manufacturing support and CAD design. The centre was no longer viewed as an execution arm but as a trusted enterprise capability. Trust is earned before transformation succeeds. Many organisations speak about trust as a leadership value. Paula views it as an operational discipline. Sharing the example of transitioning indirect tax processes, she described how local teams understandably questioned whether a newly established GBS could match years of local expertise. Discover more Communications Organizational Rather than attempting to persuade stakeholders with presentations or business cases, her team focused on partnership. They involved local experts throughout the transition, documented knowledge carefully, established governance, agreed service levels and measured performance transparently. Clubs & Organizations Only after consistently delivering quality improvements, stronger controls and measurable business outcomes did confidence grow. Strategic Planning As Paula noted, trust is not created on the day of go-live. It develops through repeated delivery, openness and credibility. Co-design replaces handover. Perhaps the strongest leadership lesson came from Paula's approach to transitions. Instead of treating migration as transferring ownership from one team to another, she described it as co-designing long-term success. Using the example of managing Brazil's complex indirect tax processes, Paula explained that the conversation was never about convincing local teams they could do better. Business & Corporate Law Instead, the dialogue focused on understanding risks together. Her team invested time travelling to local markets, walking through day-to-day operations, understanding exceptions and jointly testing controls before taking ownership. Importantly, the local experts remained partners well beyond go-live. Discover more investment That collaborative mindset reduced organisational resistance while improving operational resilience. Five leadership lessons. Its conversation reinforced several principles that extend well beyond GCCs. Financial Planning & Management * Capability creates demand more effectively than migration plans. * Trust is earned through consistent delivery, not presentations. * Credibility grows from measurable performance. * Co-design builds stronger transitions than handovers. * Strategic partnerships outlast implementation milestones. Final thoughts. As Global Capability Centres continue evolving into enterprise transformation hubs, technical capability alone will not determine success. Leaders who invest in credibility, partnership and trust create organisations that attract new opportunities naturally. Paula's experience demonstrates that the most successful GCCs don't simply execute work more efficiently. Journalism & News Industry They become organisations the business actively seeks out for its next strategic challenge. About Paula Ordoñez Angel. Paula Ordoñez Angel is the former Americas GBS Site Director and Country General Manager at Zimmer Biomet. She has more than twenty years of experience in finance, treasury and Global Business Services across healthcare and FMCG, leading large-scale transformation and capability development programmes throughout the Americas. About GCC Voices. GCC Voices is an interview series hosted by Dr Aniisu K. Verghese, featuring conversations with Global Capability Centre leaders, site directors and transformation executives on leadership, communication, change and the future of enterprise capability.
Zimmer Biomet appoints Chintan Desai as President of Asia Pacific. Fri, 17 Jul 2026 Zimmer Biomet has appointed Chintan Desai as President of its Asia Pacific region, effective immediately, strengthening its leadership as the company continues to execute its strategy across key international markets. Desai joins Zimmer Biomet from Alcon, where he most recently served as Vice President and General Manager of International Growth and Export Markets, based in Switzerland. Prior to that role, he led Alcon's surgical business across the Asia Pacific region from Singapore after joining the company in 2022. Before Alcon, Desai spent more than 22 years at GE HealthCare, building extensive experience across the medical technology sector and leading businesses throughout Asia Pacific. Announcing the appointment, Zimmer Biomet President and CEO Ivan Tornos highlighted Desai's regional expertise and leadership experience. "He knows this market, he knows how to lead and he will be a strong addition to our team," Tornos said in a statement, noting Desai's nearly three decades of leadership experience across Asia Pacific. Leadership change comes as Zimmer Biomet advances Asia Pacific strategy. Desai takes on the role at a time when Zimmer Biomet has been refining its commercial approach across several international markets. During the company's first-quarter 2026 earnings call, executives discussed softer performance outside the United States. CEO Ivan Tornos attributed part of the international results to Zimmer Biomet's decision to simplify its distribution model in markets including China by moving from a broad distributor network to one or two strategic partners. Earlier this year, then-Chief Financial Officer Suketu Upadhyay also noted that the company expected sales in China to decline slightly as it continued to reconfigure its go-to-market strategy. He added that Asia Pacific sales were expected to be lower year over year, primarily due to Japan's biennial medical device price revision, describing the adjustment as a routine part of the business. Desai succeeds Sang Yi, who will leave Zimmer Biomet on 28 August. Yi joined the company in 2013, was appointed President of Asia Pacific in 2015, and became Group President, Asia Pacific, in 2021. With decades of leadership experience across the region, Desai will now oversee Zimmer Biomet's Asia Pacific business as the company continues to strengthen its presence in one of the world's fastest-growing MedTech markets. Up next: MedTech World Asia 2026 | Hong Kong. As Asia Pacific continues to strengthen its position as a global MedTech powerhouse, the conversations defining the region's healthcare ecosystem have never been more important. From market access and commercialization to investment, cross-border collaboration, digital health, and AI, these topics will take center stage at MedTech World Asia 2026, taking place 26-28 August at the Hong Kong Convention and Exhibition Centre (HKCEC). Bringing together founders, investors, healthcare leaders, policymakers, and industry experts from across the region and beyond, the event provides a platform to explore the opportunities, challenges, and partnerships driving innovation across Asia Pacific. Be part of the conversations driving MedTech across Asia Pacific and secure your place today.
Zimmer Biomet names Chintan Desai president of Asia Pacific Region. Jul 14, 2026 WARSAW, Ind., July 14, 2026 /PRNewswire/ - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Chintan Desai has been named president of the company's Asia Pacific Region, effective immediately. "Chintan is a seasoned MedTech executive with nearly three decades of leadership experience at highly respected companies, along with deep expertise leading businesses across the Asia Pacific region," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "He knows this market, he knows how to lead, and he will be a strong addition to our team. I'm very much looking forward to the impact he'll make for our team, our customers and our Mission." Desai brings extensive proven leadership in the global medical technology industry, with deep experience across the Asia Pacific region. He joins Zimmer Biomet from Alcon, where he most recently served as vice president and general manager of International Growth and Export Markets and as a member of Alcon's International Leadership Team, based in Switzerland. Prior to that role, Desai was vice president for Alcon's Asia Pacific Surgical business based in Singapore, where he led the MedTech franchise across multiple markets in the region. Before joining Alcon, he spent more than 22 years at GE Healthcare in a variety of senior regional business leadership roles based in the United States, Singapore and Australia. His experience spans sales management, marketing, services, supply chain, finance and project management across medical devices, consumer health, digital solutions and capital equipment. Desai is a certified Chartered Accountant from India. He also completed the Executive Leadership Development Program at Kellogg School of Management at Northwestern University. He is an active volunteer and mentor for business schools and startups in the Asia Pacific region. Desai replaces Sang Yi, current group president of Asia Pacific, who will depart the company on Aug. 28 to ensure a smooth transition. Tornos added, "On behalf of the entire Zimmer Biomet team, I would like to thank Sang for his leadership and contributions over the past 13 years. He played an important role in advancing our strategy across Asia Pacific and helped drive meaningful growth for our company in a critical region of the world. We wish him all the best in his next chapter." About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. Zimmer Biomet Inc. seamlessly transform the patient experience through its innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Its legacy continues to come to life today through its progressive culture of evolution and innovation. For more information about its product portfolio, its operations in 25+ countries and sales in 100+ countries or about joining its team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet. Cautionary Note Regarding Forward-Looking Statements This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission ("SEC"). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release. | Contacts: | / | | Media | Investors | | Troy Kirkpatrick | David DeMartino | | 614-284-1926 | 646-531-6115 | | [email protected] | [email protected] | | Kirsten Fallon | Zach Weiner | | 781-779-5561 | 908-591-6955 | | [email protected] | [email protected] | SOURCE Zimmer Biomet Holdings, Inc.
Indiana University and Zimmer Biomet launch research, workforce partnership. April 21, 2026 By dan spalding news now Warsaw. WARSAW - Indiana University and Warsaw-based Zimmer Biomet have entered into a new partnership designed to accelerate technologies that improve joint replacement, bone healing, and mobility. The agreement will result in collaboration on research and development, technical training and credentialing, as well as workforce development initiatives. "This is a significant moment for Indiana University," said IU President Pamela Witten during Monday's announcement. "It's exactly the kind of partnership that reflects who we are as a university. (0:27) More innovative, more engaged, and more determined than ever to move great ideas into things that have real-world impact," she said. It appears the agreement could serve as a direct boost to Warsw's massive collection of orthopedic firms beyond just Zimmer Biomet. IU's statement on Monday says the focus will be on meeting the evolving needs of Indiana's orthopedic sector. Zimmer Biomet President Victor Tornos also celebrated the announcement that further deepens the orthopedic leader's roots in Indiana. "So when you have a bold vision, you need bold partners. And that's what Indiana University has right here. A bold vision, with bold partners, with great students," Tornos said. "Today is a very exciting day, not just for the university, for the state of Indiana, but for the world," he added. A central component of the collaboration is Zimmer Biomet's support and engagement in the Indiana Musculoskeletal Health Partnership for the Advancement of Care & Treatment, or IMPACT, an IU-led statewide consortium shaping Indiana's leadership as a global hub for orthopedic innovation, the news release said. The consortium, named a finalist in the National Science Foundation's Regional Innovation Engines competition, brings together more than 100 partners across academia, industry and government to bridge the gap between patients' unmet medical needs and the technologies that can solve them, including smarter implants and wearable diagnostics. Zimmer Biomet will also engage with faculty and students from the IU Kelley School of Business on applied, interdisciplinary projects focused on practical challenges in the orthopedic sector, including supply chain optimization, operational efficiency and innovation strategy, the news release said. The IU portion of the partnership will be led by the IU Launch Accelerator for Biosciences, known as IU LAB. "IU LAB exists to turn Indiana University's research strengths into solutions that matter in the real world," IU LAB President and CEO David Rosenberg said. "The partnership with Zimmer Biomet does exactly that: embedding industry insight, shared infrastructure and market urgency directly into its research and talent pipeline. "Together with Zimmer Biomet, we are shortening the distance between discovery and deployment while cementing Indiana as the world's leader in orthopedic innovation," Rosenberg said.
Zimmer Biomet has appointed Dr Jonathan Vigdorchik as Chief Science, Technology and Medical Affairs Officer, effective 14 April. He will oversee the company's global technology portfolio, including AI, robotics, smart implants and data, whilst managing medical education strategy and the Global Advisory Board. Dr Vigdorchik previously served as Zimmer Biomet's Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants. He is a board-certified orthopaedic surgeon at Hospital for Special Surgery in New York and Associate Professor of Orthopaedic Surgery at Weill Cornell Medical College. The appointment reflects Zimmer Biomet's focus on advancing its robotic and enabling technologies, with Dr Vigdorchik reporting to Chairman, President and CEO Ivan Tornos. He will help accelerate the company's innovation roadmap and strengthen clinical engagement.